Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.

Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, Atreja A, Ron Y, Swaminath A, Shah S, Hart A, Lakatos PL, Ellul P, Israeli E, Svendsen MN, van der Woude CJ, Katsanos KH, Yun L, Tsianos EV, Nathan T, Abreu M, Dotan I, Lashner B, Brynskov J, Terdiman JP, Higgins PD, Chaparro M, Ben-Horin S.

Inflamm Bowel Dis. 2012 Nov;18(11):2026-33. doi: 10.1002/ibd.22902. Epub 2012 Jan 31.

2.
3.

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.

Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.

Dig Liver Dis. 2004 May;36(5):342-7.

PMID:
15191204
4.

Infliximab dose intensification in Crohn's disease.

Regueiro M, Siemanowski B, Kip KE, Plevy S.

Inflamm Bowel Dis. 2007 Sep;13(9):1093-9.

PMID:
17480021
5.

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.

Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.

Am J Gastroenterol. 2002 Sep;97(9):2357-63.

6.

Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease.

Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T.

Inflamm Bowel Dis. 2012 Aug;18(8):1480-7. doi: 10.1002/ibd.21886. Epub 2011 Oct 10.

PMID:
21987418
7.

Infliximab maintenance therapy for fistulizing Crohn's disease.

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ.

N Engl J Med. 2004 Feb 26;350(9):876-85.

8.

Infliximab use in luminal Crohn's disease.

Richter JA, Bickston SJ.

Gastroenterol Clin North Am. 2006 Dec;35(4):775-93. Review.

PMID:
17129813
9.

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.

N Engl J Med. 2003 Feb 13;348(7):601-8.

10.

Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.

Kinney T, Rawlins M, Kozarek R, France R, Patterson D.

Am J Gastroenterol. 2003 Mar;98(3):608-12.

PMID:
12650795
11.
12.

Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.

Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.

Am J Gastroenterol. 2000 Nov;95(11):3189-94.

PMID:
11095340
13.

The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.

Kierkus J, Dadalski M, Szymanska E, Oracz G, Wegner A, Gorczewska M, Szymanska S, Woynarowski M, Ryzko J.

Eur J Gastroenterol Hepatol. 2012 May;24(5):495-500. doi: 10.1097/MEG.0b013e32835159f2.

PMID:
22387887
14.

Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.

Rutgeerts PJ.

Aliment Pharmacol Ther. 1999 Sep;13 Suppl 4:9-15; discussion 38. Review.

15.

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group.

Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. Epub 2006 Dec 3.

PMID:
17324398
16.

Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.

Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.

Rom J Gastroenterol. 2003 Mar;12(1):7-13.

PMID:
12673373
17.

Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.

Lamireau T, Cézard JP, Dabadie A, Goulet O, Lachaux A, Turck D, Maurage C, Morali A, Sokal E, Belli D, Stoller J, Cadranel S, Ginies JL, Viola S, Huet F, Languepin J, Lenaerts C, Bury F, Sarles J; French-Speaking Group for Pediatric Gastroenterology Nutrition.

Inflamm Bowel Dis. 2004 Nov;10(6):745-50.

PMID:
15626892
18.

Infliximab dose intensification by shortening infusion intervals.

Magro F, Bastos R, Marques M, Costa Santos C.

Inflamm Bowel Dis. 2008 Mar;14(3):432-4. No abstract available.

PMID:
18022873
19.

Predictors of response to infliximab in luminal Crohn's disease.

Laharie D, Salzmann M, Boubekeur H, Richy F, Amouretti M, Quinton A, Couzigou P, Lamouliatte H, Zerbib F.

Gastroenterol Clin Biol. 2005 Feb;29(2):145-9.

20.

Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5 years.

Lönnkvist MH, Befrits R, Lundberg JO, Lundahl J, Fagerberg UL, Hjortswang H, van Hage M, Hellström PM.

Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1168-76.

PMID:
19757522

Supplemental Content

Support Center